2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness

By afschroeder • August 5, 2025

Bhimraj A, Falck-Ytter Y, Baden LR, Bedimo R, Cawcutt K, Cheng VC, Chew KW, Chiotos K, Daar ES, Dzierba AL, Glidden DV, Hardy EJ, Johnson S, Kim AY, Li JZ, MacBrayne C, Martin GS, Nadig N, Nakamura MM, Pearson JC, Riley L, Shafer RW, Shoham S, Shumaker AH, Tebas P, Tien PC, Loveless J, Morgan RL, Gandhi RT. 2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Pemivibart for Pre-exposure Prophylaxis, Vilobelimab for Critical Illness, and Abatacept or Infliximab for Severe or Critical Illness. Clin Infect Dis. 2025 Aug 4:ciaf424. doi: 10.1093/cid/ciaf424. Epub ahead of print. PMID: 40757658.

Tags: abatacept, covid-19, Harbor UCLA, Infectious Diseases, infliximab, pemivibart, Publications, vilobelimab

Predictors of diffuse coronary artery calcium phenotype in adults aged ≥ 75: The Atherosclerosis Risk in Communities (ARIC) study

Gami A, Zou S, Dardari ZA, Dudum R, Mok Y, Budoff MJ, Lutsey PL, Howard CM, Couper D, Matsushita K, Blaha MJ. Predictors of diffuse[...]

Parasex generates highly recombinant progeny in Candida albicans with increased virulence

Fillinger RJ, Mishra A, Loza L, Sircaik S, Carriel CC, Mackey AI, Stratton TD, Filler SG, Selmecki AM, Bennett RJ, Anderson MZ. Parasex generates highly[...]

Pulmonary Obstruction and Age, Not Activity, Associate With Muscle Oxidative Impairment in Smokers With and Without COPD

Adami A, Duan F, Calmelat RA, Chen Z, Casaburi R, Rossiter HB. Pulmonary Obstruction and Age, Not Activity, Associate With Muscle Oxidative Impairment in Smokers[...]